Has Hemal Gada, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,801,250 in general payments to Hemal Gada, MD across 1,809 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Hemal Gada, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Hemal Gada, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Hemal Gada, MD

Cardiovascular Disease · Wormleysburg, PANPI 1386852390

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,429,183 of the $1,801,250 with a category attached, or 79.3%. Medtronic accounts for 89.8% of it on its own, with 17 other manufacturers making up the rest. Among cardiovascular disease clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,801,250in general payments, 2019–2025

Across 1,809 payments — averaging $995.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$1.6M
Abbott$62K
Boston Scientific$57K
Edwards Lifesciences$32K
Bard Peripheral Vascular, Inc.$18K
W. L. Gore & Associates, Inc.$6K
plus $9K from 12 others

$4,879,025in research payments, 2019–2025

Across 942 payments — averaging $5179.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Medtronic$2.9M
Edwards Lifesciences$1.2M
Boston Scientific$450K
Abbott$260K
Daiichi Sankyo Inc.$21K
W. L. Gore & Associates, Inc.$12K

$18,000in ownership & investment interests, 2019–2025

Across 1 payment — averaging $18,000 each. An ownership or investment interest held by the physician or an immediate family member.

Pi-cardia, Inc.$18K

What the payments were for

Consulting fees$125,6667%
Speaking & faculty fees$1,429,18379%
Grants$890%
Travel & lodging$192,91911%
Food & beverage$41,0792%
Education$12,0311%
Other$2820%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	1,496	$1,617,170
Abbott	140	$61,898
Boston Scientific	102	$57,467
Edwards Lifesciences	33	$32,245
Bard Peripheral Vascular, Inc.	5	$18,119
W. L. Gore & Associates, Inc.	4	$5,550
Opsens Inc.	3	$2,750
GE HealthCare	3	$2,450
Jenavalve Technology, Inc.	2	$1,427
Atricure, Inc.	8	$962
Cardiva Medical, Inc.	2	$539
Inari Medical, Inc.	2	$339
Amgen	1	$103
Terumo Medical Corporation	1	$77
Recor Medical Inc	1	$76
Pi-cardia, Inc.	2	$39
E.r. Squibb & Sons, L.L.C.	1	$26
Covidien LP	3	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,801,250 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$211,807

Medicare patients

374

Services billed

872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
JardianceEmpagliflozin	98	$78,665
EliquisApixaban	87	$60,887
EntrestoSacubitril/Valsartan	27	$21,358
Metoprolol Succinate	102	$1,731
Atorvastatin Calcium	76	$689
Metoprolol Tartrate	69	$610
Rosuvastatin Calcium	15	$527
Warfarin Sodium	41	$516
ClopidogrelClopidogrel Bisulfate	47	$393
JantovenWarfarin Sodium	20	$366
Amlodipine Besylate	47	$354
Furosemide	85	$177
Amiodarone Hcl	11	$129
Hydrochlorothiazide	14	$124
Spironolactone	20	$101

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Wormleysburg

Benjamin KalsmithPgh$1.7M
Peter KoweyWynnewood$1.5M
Paul ForfiaPhiladelphia$1.2M
Quang BuiPhiladelphia$933K
Rhian DaviesYork$853K
Sarang MangalmurtiBryn Mawr$728K
Sabahat BokhariAllentown$578K
George GabrielPittsburgh$563K
Rajesh DaveCamp Hill$442K
Matthew MartinezAllentown$419K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →